Discovery Experimental & Development Inc. (DEDI)

Please Select A Category

It clearly appears that Eldepryl Approved By The FDA Was A Serious Farce That Killed People

Replace Title

Our bodies appear to know when our body has produced enough of any substance to sustain our lives in a normal fashion. Our body normally will slow down, or stop the production if there is too much of any one substance; or increase the needed substance if there is too little. These are the checks and balances of our bodies, if all is functioning properly.

Many scientists claim these checks and balances are all encompassed in genetics; like genetic clocks, which appear to run out of time as we age. However, there is some evidence that the genetic clocks may be controlled, at least in some part by the brain.

The point is, it appears very clear that the administration of Levodopa on a continual basis, slows, or stops the already compromised Substantia Nigra tissue from emitting the life sustaining dopamine and the Parkinson's patients die before they normally would without the use, or sporadic use of Levodopa. Continued use, appears much worse and causes a much earlier death, used on a continual basis.

Eldepryl's Dangers And Non-Effectiveness. After the FDA approved Eldepryl, Kimball and DEDI in 1990 began to closely examine Eldepryl. Unbeknownst to Kimball and DEDI at the time, another foreign research laboratory was also closely examining the active ingredient within Eldepryl; Selegiline HCL.

Additionally, unbeknownst to DEDI a scientific research group in England had just started trials using the exact 2 products the FDA had approved 1 year earlier; Levodopa and Selegiline HCL against using just the already approved Levodopa alone.

It Clearly Appeared Both Scientific Foreign Study Groups From Different Countries Believed That The FDA Approval Of Eldepryl To Be Used With Levodopa Was Rigged

In 1991 when DEDI found the Selegiline HCL content in Eldepryl was only 98% pure it was reported to all Government and state agencies, as was the methamphetamine content.

By early 1992 DEDI knew from its own studies and those studies the University of Toronto (UOT) were conducting, that DEDI's Liquid Deprenyl Citrate (LDC) worked by itself and that Eldepryl did not work at all.

Both DEDI and UOT research teams became obsessed with what other contaminates were within the Selegiline HCL in Eldepryl. By this time both DEDI and the UOT firmly believed that the chemical Selegiline HCL may never be able to be perfected so it could be effective in any consistent manner because of its chemical make-up.

Around the mid-1992, the research team at Toronto discovered an unknown contaminate within the Selegiline HCL in Eldepryl. Later Dr. Barltrop, head scientist at DEDI, believed he had identified the unknown contaminate as a neurotoxin. Toxic to anyone using the product.

The FDA and Florida State Health agencies were alerted, however they could care less.

At this point DEDI knew that Somerset/Mylan and Bolar Pharmaceuticals had to have known about the undisclosed contaminant.

DEDI went as far as notifying the USP who reviews the testing of all products and reports those findings to the FDA. The USP could care less about the new found contaminate believed to be toxic.

We asked the USP to send DEDI all Somerset's testing results of Eldepryl and any reports they had on the Selegiline HCL that Eldepryl contained. The USP was totally uncooperative. DEDI demanded all the results and the USP finally gave in and sent DEDI a copy of all testing results; charging DEDI a fortune for about 50 copies, somewhere in the vicinity of $1,800.00.

The testing results revealed exactly how Somerset covered up the unknown contaminate. It appeared the USP inadvertently included correspondence to them from a foreign company they should not have provided DEDI. This correspondence from a foreign research company spelled out the fact that Selegiline HCL had an unknown contaminate and exactly where the contaminate would reveal itself on the exact same tests submitted by Somerset/Mylan/Bolar to the USP. The USP did not inadvertently mail DEDI any copy of what the USP's reply to the foreign research company was.

The unknown contaminate reflected by the foreign company to the USP was exactly the same contaminate the UOT research team came up with using the exact same test; which was the exact same test Somerset submitted to the USP and FDA.

What Somerset/Mylan/Bolar did when they supplied their test results to the USP and FDA is they cut the test short; stopping the test before the contaminate revealed itself. A total fraud further jeopardizing the lives of terminal Parkinson's patients for the almighty dollar.

Kimball and his associates have all the communications and test results which will ultimately be scanned into this site and explain all.

Not long after the encounter that DEDI had with the USP, FDA and Florida Department of Health; the English scientists released for publication the results of their 5-year study, which entailed using the FDA approved method for treating Parkinson's patients; Levodopa with Eldepryl (Selegiline HCL) versus treating Parkinson's patients with Levodopa alone.

The Results From The British Trials Were Conclusive:

The FDA Approved Drugs, Levodopa And Selegiline HCL Eldepryl Killed Parkinson's Patients At A Much Higher Rate Than Levodopa Alone

Kimball was indicted and DEDI put out of business in 1999. Imprisoned in 2000 by Somerset Pharmaceuticals, the FDA, a corrupt judicial system and LDC disappeared. You can review what happened to Kimball in his Declaration, Condensed Declaration, Rigged Trials Across The US, and Corrupt Government Employees.

One thing good came out of Kimball's rigged trial. Dr. Ira Shoulson "admitted" in court testimony that Eldepryl did not work. That testimony will be scanned into this website shortly.

Representatives were present from the FDA when Dr. Shoulson made that admission in court in early 2000.

What Somerset/Mylan/Bolar Accomplished

Somerset/Mylan/Bolar (SMB) in concert with the FDA, USP, corrupt judges and prosecutors had not only put DEDI out of business and its President in prison, it stopped the US public from acquiring any of DEDI's products to either save their lives, or improve their quality of life.

Further: Eldepryl's FDA approval was gained mostly from monies received from the Government and donations to Dr. Shoulson's Data Top Study.

After FDA approval, SMB sold a 30-day supply of Eldepryl; (60 5mg tablets), to people afflicted with a terminal disease for an average of $110.00 per bottle nationwide.

The cost of producing a month's supply of Eldepryl, (300mg of Selegiline HCL) is about 10 cents; not ten dollars; 10 cents. The glass bottle that the 60 tablets of Eldepryl came in would have cost more than its contents.

Somerset reported via its owner Mylan laboratories, stock reports that Eldepryl sales by the late 1990's had generated revenues of close to one billion dollars. All this money generated from the sale of one product used in combination with another product to an extreme minority of people in our country (less than 1%) afflicted with a deadly terminal disease.

What SMB Did, With Full Consent From The FDA, USP And Others Is To Take Full Advantage Of The Compromised Sick And Dying, Price Gouge Them With A Fraudulent Product, Causing Some To Die Before Their Time, And

Laugh ALL THE WAY TO THE BANK